Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8406312 | 0.84 | LIPA (0.52) | LIPAKMT2A | |
| SCHEMBL9662429 | 0.80 | LIPA (0.44) | LIPAKMT2A | |
| SCHEMBL12208661 | 0.80 | LIPA (0.44) | LIPAKMT2A | |
| SCHEMBL8242270 | 0.78 | HPGD (0.45) | LIPAKMT2A | |
| SCHEMBL16722803 | 0.78 | LIPA (0.47) | LIPAKMT2A | |
| SCHEMBL25015431 | 0.78 | SLC6A1 (0.38) | LIPA | |
| SCHEMBL17445699 | 0.78 | LIPA (0.35) | LIPA | |
| SCHEMBL10193780 | 0.78 | LIPA (0.30) | LIPA | |
| SCHEMBL5531811 | 0.78 | LIPA (0.33) | LIPA | |
| SCHEMBL25096019 | 0.77 | LIPA (0.34) | LIPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | LIPA 2599/4885KMT2A 4174/4885 |
| US-10017556-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | LIPA 2599/4885KMT2A 4174/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | LIPA 2599/4885KMT2A 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.